OTCMKTS:CYDY - CytoDyn Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CytoDyn Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.20 +0.05 (+4.35 %) (As of 01/29/2020 08:35 AM ET) Add Compare Today's Range$1.16Now: $1.20▼$1.2550-Day Range$0.28MA: $0.81▼$1.1552-Week Range$0.06Now: $1.20▼$1.25Volume4.47 million shsAverage Volume2.71 million shsMarket Capitalization$522.10 millionP/E RatioN/ADividend YieldN/ABeta1.15 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email CytoDyn Inc, a clinical-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb treatment substitution trial, Phase IIb extension study, Phase IIb/III pivotal trial, and Phase IIb/III investigative trial for HIV; and Phase II trial for graft-versus-host disease. Read More… Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:CYDY Previous SymbolNASDAQ:CYDY CUSIP23283M101 CIK1175680 Webhttp://www.cytodyn.com/ Phone360-980-8524Debt Debt-to-Equity RatioN/A Current Ratio0.11 Quick Ratio0.11Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.03) per share Price / Book-40.00Profitability EPS (Most Recent Fiscal Year)($0.21) Net Income$-56,190,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-301.48%Miscellaneous Employees6 Outstanding Shares435,080,000Market Cap$522.10 million Next Earnings DateN/A OptionableNot Optionable Receive CYDY News and Ratings via Email Sign-up to receive the latest news and ratings for CYDY and its competitors with MarketBeat's FREE daily newsletter. OTC:CYDY Rates by TradingView CytoDyn (OTCMKTS:CYDY) Frequently Asked Questions What is CytoDyn's stock symbol? CytoDyn trades on the OTCMKTS under the ticker symbol "CYDY." How were CytoDyn's earnings last quarter? CytoDyn Inc (OTCMKTS:CYDY) released its quarterly earnings results on Tuesday, October, 9th. The biotechnology company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.06) by $0.01. View CytoDyn's Earnings History. What price target have analysts set for CYDY? 1 Wall Street analysts have issued 12-month target prices for CytoDyn's shares. Their forecasts range from $1.50 to $1.50. On average, they anticipate CytoDyn's stock price to reach $1.50 in the next twelve months. This suggests a possible upside of 25.0% from the stock's current price. View Analyst Price Targets for CytoDyn. What is the consensus analysts' recommendation for CytoDyn? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytoDyn in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CytoDyn. What are Wall Street analysts saying about CytoDyn stock? Here are some recent quotes from research analysts about CytoDyn stock: 1. According to Zacks Investment Research, "CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed Phase 2 clinical trials with demonstrated antiviral activity in humans and is currently in Phase 3 development. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy. " (1/28/2020) 2. HC Wainwright analysts commented, "Our 12-month price target is derived from an estimated market value of the firm at $560M. It includes a discounted cash flow-based asset value of $566M for leronlimab in the HIV indication alone, with a 15% discount rate, 2% terminal growth rate, 80% probability of success, and excluding $6M debt." (3/18/2019) Has CytoDyn been receiving favorable news coverage? Media coverage about CYDY stock has been trending negative on Wednesday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. CytoDyn earned a daily sentiment score of -2.0 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the near term. View News Stories for CytoDyn. Who are some of CytoDyn's key competitors? Some companies that are related to CytoDyn include Principia Biopharma (PRNB), Zymeworks (ZYME), Pacira Biosciences (PCRX), Insmed (INSM), Akcea Therapeutics (AKCA), Arvinas (ARVN), Tricida (TCDA), Forty Seven (FTSV), Alder Biopharmaceuticals (ALDR), Ligand Pharmaceuticals (LGND), Constellation Pharmaceuticals (CNST), Corcept Therapeutics (CORT), Theravance Biopharma (TBPH), Innoviva (INVA) and Amneal Pharmaceuticals (AMRX). What other stocks do shareholders of CytoDyn own? Based on aggregate information from My MarketBeat watchlists, some companies that other CytoDyn investors own include Rexahn Pharmaceuticals (REXN), Senseonics (SENS), Sangamo Therapeutics (SGMO), United Therapeutics (UTHR), Achillion Pharmaceuticals (ACHN), Opko Health (OPK), Tenax Therapeutics (TENX), Matinas BioPharma (MTNB), Exelixis (EXEL) and Pieris Pharmaceuticals (PIRS). Who are CytoDyn's key executives? CytoDyn's management team includes the folowing people: Dr. Nader Z. Pourhassan, CEO, Pres & Director (Age 56)Mr. Michael D. Mulholland, CFO, Treasurer & Corp. Sec. (Age 67)Dr. Denis R. Burger, Scientific Consultant (Age 75)Dr. Richard G. Pestell M.B.A., M.D., MBA. M.D., Ph.D., Vice Chairman & Chief Medical OfficerDr. Nitya G. Ray, Chief Technology Officer & Head of Process Sciences, Manufacturing and Supply Chain (Age 66) How do I buy shares of CytoDyn? Shares of CYDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is CytoDyn's stock price today? One share of CYDY stock can currently be purchased for approximately $1.20. How big of a company is CytoDyn? CytoDyn has a market capitalization of $522.10 million. The biotechnology company earns $-56,190,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. CytoDyn employs 6 workers across the globe.View Additional Information About CytoDyn. What is CytoDyn's official website? The official website for CytoDyn is http://www.cytodyn.com/. How can I contact CytoDyn? CytoDyn's mailing address is 1111 MAIN STREET SUITE 660, VANCOUVER WA, 98660. The biotechnology company can be reached via phone at 360-980-8524 or via email at [email protected] MarketBeat Community Rating for CytoDyn (OTCMKTS CYDY)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 167 (Vote Outperform)Underperform Votes: 170 (Vote Underperform)Total Votes: 337MarketBeat's community ratings are surveys of what our community members think about CytoDyn and other stocks. Vote "Outperform" if you believe CYDY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYDY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/29/2020 by MarketBeat.com StaffFeatured Article: Most Active Stocks: Dollar Volume vs Share Volume
